You are Watching: Post ASBMR Review: Amgen's Denosumab Lowers Fracture Risk, Makes the News at the American Society for Bone and Mineral Research (ASB...

You are Watching: Post ASBMR Review: Denosumab to Seize Low Hanging Fruit in Osteoporosis Market, with the Potential to Become 1st Line Treatment. Amg...

You are Watching: Post ASBMR Review: A quick look Pfizer's Fablyn, and Merck Odanacatib. Mike and Jean-Loup take a quick look at some of the other dat...

You are Watching: Targanta's Antibiotic Shows Promise, And Overcomes the Challenges it Faced When Previously Developped at Lilly and InterMune Oritava...

You are Watching: Targanta Confident and Prepared for FDA Panel Review of Lead Compound Oritavancin Mark and Joel delve into the clincal trials and re...

You are Watching: Targanta Attacking $1.2Bn Antibiotic Market with Resistance Adverse Drug, Do-or-Die! Mark and Joel review the competitive landscape ...

You are Watching: Alexza's Staccato: Vaporized Drugs in Multiple Indications, with a Safe and Effective Profile The Staccato system combines drug and ...

You are Watching: Alexza's Eulogistic Symphony Deal, Partnering and Sales Strategies, and Cash 'till the Summer of 2010 Ted Tenthoff asks Tom King of ...

You are Watching: Making Money in Biotech, the JMP Securities Way - Part I: State of the Industry Mid Year Report The biotech sector is driven by news...

You are Watching: Making Money in Biotech, the JMP Securities Way - Part II: Finding the Tipping Point Which companies are likely to have news that ca...